{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T11:34:42Z","timestamp":1772537682304,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s11096-023-01668-9","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T18:03:06Z","timestamp":1703872986000},"page":"421-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using claims database: a retrospective cohort study"],"prefix":"10.1007","volume":"46","author":[{"given":"Takezo","family":"Tsutsumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Momo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-0785","authenticated-orcid":false,"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,29]]},"reference":[{"key":"1668_CR1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18\u201355. https:\/\/doi.org\/10.1093\/cid\/ciq146.","journal-title":"Clin Infect Dis."},{"key":"1668_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/IDR.S54125","volume":"8","author":"T O\u2019Driscoll","year":"2015","unstructured":"O\u2019Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015;8:217\u201330. https:\/\/doi.org\/10.2147\/IDR.S54125.","journal-title":"Infect Drug Resist"},{"key":"1668_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","volume":"81","author":"AK Thabit","year":"2019","unstructured":"Thabit AK, Fatani DF, Bamakhrama MS, et al. Antibiotic penetration into bone and joints: an updated review. Int J Infect Dis. 2019;81:128\u201336. https:\/\/doi.org\/10.1016\/j.ijid.2019.02.005.","journal-title":"Int J Infect Dis"},{"key":"1668_CR4","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1128\/AAC.03688-14","volume":"59","author":"AF Shorr","year":"2015","unstructured":"Shorr AF, Lodise TP, Corey GR, et al. Analysis of the Phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59:864\u201371. https:\/\/doi.org\/10.1128\/AAC.03688-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"1668_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1128\/AAC.47.6.1824-1831.2003","volume":"47","author":"E Rubinstein","year":"2003","unstructured":"Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid\u2019s clinical safety and tolerability: comparator-controlled Phase III studies. Antimicrob Agents Chemother. 2003;47:1824\u201331. https:\/\/doi.org\/10.1128\/AAC.47.6.1824-1831.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"1668_CR6","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1248\/yakushi.19-00010","volume":"139","author":"T Tsutsumi","year":"2019","unstructured":"Tsutsumi T, Imai S, Yamada K, et al. Verification of relationship between administration of linezolid and vomiting. Yakugaku Zasshi. 2019;139:1055\u201361. https:\/\/doi.org\/10.1248\/yakushi.19-00010.","journal-title":"Yakugaku Zasshi"},{"key":"1668_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00228-021-03221-x","volume":"78","author":"T Tsutsumi","year":"2022","unstructured":"Tsutsumi T, Imai S, Kashiwagi H, et al. Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study. Eur J Clin Pharmacol. 2022;78:279\u201386. https:\/\/doi.org\/10.1007\/s00228-021-03221-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"1668_CR8","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1128\/AAC.47.9.2775-2780.2003","volume":"47","author":"ME Brier","year":"2003","unstructured":"Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47:2775\u201380. https:\/\/doi.org\/10.1128\/AAC.47.9.2775-2780.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"1668_CR9","unstructured":"Zyvox\u00ae package insert, U.S Food & Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/021130s044,021131s041,021132s043lbl.pdf. Accessed 31 Oct 2023."},{"key":"1668_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1086\/318486","volume":"32","author":"E Rubinstein","year":"2001","unstructured":"Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402\u201312. https:\/\/doi.org\/10.1086\/318486.","journal-title":"Clin Infect Dis"},{"key":"1668_CR11","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/340353","volume":"34","author":"DL Stevens","year":"2002","unstructured":"Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481\u201390. https:\/\/doi.org\/10.1086\/340353.","journal-title":"Clin Infect Dis"},{"key":"1668_CR12","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/jac\/dkt133","volume":"68","author":"Y Nukui","year":"2013","unstructured":"Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68:2128\u201333. https:\/\/doi.org\/10.1093\/jac\/dkt133.","journal-title":"J Antimicrob Chemother"},{"key":"1668_CR13","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375:2293\u20137. https:\/\/doi.org\/10.1056\/NEJMsb1609216.","journal-title":"N Engl J Med"},{"key":"1668_CR14","unstructured":"United States Food and Drug Administration. Real-world evidence. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence. Accessed 31 Oct 2023."},{"key":"1668_CR15","unstructured":"JMDC website. https:\/\/www.jmdc.co.jp\/en\/. Accessed 31 Oct 2023."},{"key":"1668_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77:835\u201364.","journal-title":"Am J Health Syst Pharm"},{"key":"1668_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clinthera.2010.01.019","volume":"32","author":"E Chiappini","year":"2010","unstructured":"Chiappini E, Conti C, Galli L, et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010;32:66\u201388. https:\/\/doi.org\/10.1016\/j.clinthera.2010.01.019.","journal-title":"Clin Ther"},{"key":"1668_CR18","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1086\/503839","volume":"42","author":"KR Lawrence","year":"2006","unstructured":"Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42:1578\u201383. https:\/\/doi.org\/10.1086\/503839.","journal-title":"Clin Infect Dis"},{"key":"1668_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0091270010366445","volume":"51","author":"K Gandelman","year":"2011","unstructured":"Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229\u201336. https:\/\/doi.org\/10.1177\/0091270010366445.","journal-title":"J Clin Pharmacol"},{"key":"1668_CR20","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356\u201367. https:\/\/doi.org\/10.1056\/NEJMra1515442.","journal-title":"N Engl J Med"},{"key":"1668_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1213\/ANE.0000000000004833","volume":"131","author":"TJ Gan","year":"2020","unstructured":"Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131:411\u201348. https:\/\/doi.org\/10.1213\/ANE.0000000000004833.","journal-title":"Anesth Analg"},{"key":"1668_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1586\/erp.11.47","volume":"11","author":"L Schwartzberg","year":"2011","unstructured":"Schwartzberg L, Jackson J, Jain G, et al. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea\/vomiting. Expert Rev Pharmacoecon Outcomes Res. 2011;11:481\u20138. https:\/\/doi.org\/10.1586\/erp.11.47.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1668_CR23","unstructured":"Katz, MH. Evaluating Clinical and Public Health Interventions: A Practical Guide to Study Design and Statistics. Cambridge University Press; 2010. [Japanese Edition] ISBN: 978\u20134\u201389592\u2013757\u20134, pp. 105\u20136"},{"key":"1668_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786.","journal-title":"Multivariate Behav Res"},{"key":"1668_CR25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/0091270009337947","volume":"49","author":"S Abe","year":"2009","unstructured":"Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49:1071\u20138. https:\/\/doi.org\/10.1177\/0091270009337947.","journal-title":"J Clin Pharmacol"},{"key":"1668_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/pds.5636","volume":"32","author":"H Yamana","year":"2023","unstructured":"Yamana H, Konishi T, Yasunaga H. Validation studies of Japanese administrative health care data: A scoping review. Pharmacoepidemiol Drug Saf. 2023;32:705\u201317. https:\/\/doi.org\/10.1002\/pds.5636.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1668_CR27","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJM200511243532123","volume":"353","author":"A Soriano","year":"2005","unstructured":"Soriano A, Mir\u00f3 O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med. 2005;353:2305\u20136. https:\/\/doi.org\/10.1056\/NEJM200511243532123.","journal-title":"N Engl J Med"},{"key":"1668_CR28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/jcpt.12681","volume":"43","author":"P Ioannou","year":"2018","unstructured":"Ioannou P, Stavroulaki M, Mavrikaki V, et al. A case of severe hyponatremia due to linezolid-induced SIADH. J Clin Pharm Ther. 2018;43:434\u20136. https:\/\/doi.org\/10.1111\/jcpt.12681.","journal-title":"J Clin Pharm Ther"},{"key":"1668_CR29","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/jcpt.13245","volume":"45","author":"Y Dai","year":"2020","unstructured":"Dai Y, Wang Y, Zeng Y, et al. Linezolid and the risk of lactic acidosis: data mining and analysis of the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2020;45:1422\u20136. https:\/\/doi.org\/10.1111\/jcpt.13245.","journal-title":"J Clin Pharm Ther"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01668-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-023-01668-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01668-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T15:03:37Z","timestamp":1711206217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-023-01668-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1668"],"URL":"https:\/\/doi.org\/10.1007\/s11096-023-01668-9","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}